- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | Pharming Group N.V.: Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31 | 274 | GlobeNewswire (Europe) | Leiden, the Netherlands, July 17, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second... ► Artikel lesen | |
| 24.06. | Pharming Group N.V. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 24.06. | Pharming Group N.V.: Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis | 8 | GlobeNewswire (USA) | ||
| 11.06. | Pharming Group N.V. - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 11.06. | Pharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders | 375 | GlobeNewswire (Europe) | Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM)... ► Artikel lesen | |
| 28.05. | Pharming Group N.V.: Pharming Group to participate in June investor conferences | 412 | GlobeNewswire (Europe) | Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences... ► Artikel lesen | |
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 09.05. | Pharming GAAP EPS of -$0.02 beats by $0.01, revenue of $79.09M beats by $15.15M | 3 | Seeking Alpha | ||
| 08.05. | Pharming Group N.V. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 08.05. | Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update | 567 | GlobeNewswire (Europe) | First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting... ► Artikel lesen | |
| 30.04. | Pharming Group N.V.: Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director | 5 | GlobeNewswire (USA) | ||
| 30.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 25.04. | Pharming Group N.V.: Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) | 6 | GlobeNewswire (USA) | ||
| 24.04. | H.C. Wainwright maintains Buy rating on Pharming Group stock | 15 | Investing.com | ||
| 24.04. | NICE issues final guidance endorsing Pharming's APDS therapy | 3 | Pharmaceutical Business Review | ||
| 24.04. | Pharming Group N.V.: Pharming Group to report first quarter 2025 financial results on May 8 | 447 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results... ► Artikel lesen | |
| 23.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.04. | Pharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDS | 488 | GlobeNewswire (Europe) | For media and investors only
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS
Recommended for adult and pediatric patients 12 years of age and older... ► Artikel lesen | |
| 03.04. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Q4/24 results/pipeline expansion - Buy | 481 | dpa-AFX | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 03.04.2025 / 17:08 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer... ► Artikel lesen | |
| 03.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.04. | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | 5 | SEC Filings |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,705 | +1,12 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,263 | -3,34 % | PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications | ||
| CENTOGENE | 0,130 | +22,64 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 2,980 | -2,10 % | Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset | ||
| BIOMERIEUX | 124,20 | -1,27 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| CYCLACEL | 13,772 | +2,01 % | Cyclacel Pharmaceuticals, Inc. - S-4, Registration of securities, business combinations | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 28,000 | +2,19 % | Genus: Underlying Group Trading In-line With Expectations | LONDON (dpa-AFX) - Genus (GNS.L) issued trading update for fiscal year ended 30 June 2025. The Group said it recorded strong underlying Group trading in-line with expectations. As a result of... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,390 | -3,47 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 23,200 | +0,87 % | Analyst Expectations For AnaptysBio's Future | ||
| ABIONYX PHARMA | 1,288 | +4,89 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| AKESO | 16,200 | +0,62 % | Akeso, Inc.: Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer | HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in... ► Artikel lesen | |
| MEIRAGTX | 7,050 | -0,70 % | MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease | - This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits... ► Artikel lesen | |
| MAAT PHARMA | 4,410 | +0,92 % | MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,071 | -8,14 % | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,59 % bei einem Aktienkurs von 8,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.